Vigabatrin bei therapieresistenten Epilepsien

Publisher Website
Google Scholar
Abstract
The antiepileptic activity of Vigabatrin (2-4g) was evaluated in an add-on single blind study in patients with therapy-refractory seizures with focal onset. There were 5 drop outs during the observation period (6 months). 11 of 22 patients with complex partial seizures had a reduction in seizure frequency of more than 50%. 7 out of 10 patients with secondary generalised tonic clonic seizures experienced an increase. Seizure intensity was decreased in 15 patients. Reduction of comedication (carbamazepine) in 4 patients led to a prompt increase of seizure frequency. Blood levels of Vigabatrin showed marked interindividual variations. Side effects in 15 patients (drowsiness, dizziness, weight gain) were mild and treatment.

This publication has 0 references indexed in Scilit: